Novel MDM2 inhibitors (e.g., DS-3032b, AMG-232) in combination with hypomethylating agents (HMAs) are now under evaluation in clinical trials (NCT03634228, NCT03041688) for patients with newly diagnosed and relapsed/refractory AML. This evidence concerns the gene MDM2 and acute myeloid leukemia.